Dr Nihanthy D S

Dr. Dr Nihanthy D S

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
DSDr Nihanthy D S
Dr Nihanthy D S
KSKinjal Singh
Kinjal Singh
SRSAMEER RASTOGI
SAMEER RASTOGI
NBNiranjan Biswal
Niranjan Biswal
ASAkash Singh
Akash Singh
SSStanzin Spalkit
Stanzin Spalkit
PURPOSE: Sarcomas exhibit clinicopathologic heterogeneity, leading to diagnostic and therapeutic uncertainty. This study assesses the clinical value of integrating targeted RNA-based next-generation sequencing (NGS) into a multidisciplinary sarcoma workflow to improve diagnosis, enable comprehensive molecular characterization, and inform personalized treatment strategies. METHODS: In this prospective single-center study, 68 patients with suspected or confirmed soft tissue sarcoma underwent RNA-based NGS using a 138-gene fusion panel, integrated within a multidisciplinary sarcoma framework. Genomic findings integrated with histopathology and immunohistochemistry for diagnostic reclassification and treatment changes. RESULTS: Of 70 patients advised RNA-based NGS, 68 (97.1%) were evaluable (median age, 38.5 years). Soft tissue sarcomas predominated (77.1%), with 67.1% presenting with advanced disease. Initial histology included 17 round cell sarcomas (RC), 19 undifferentiated sarcomas (US), and 34 other subtypes. Among evaluable RC cases (n = 16), NGS identified diagnostic fusions in 87.5%, enabling reclassification in 68.7% and treatment change in 18.7%. In US, fusions were detected in 21.1%, all reclassified, with treatment altered in 75%. In other subtypes, fusions were found in 48.4%, enabling reclassification in 39.3% and treatment impact in 21.2%. Nondiagnostic mutations (eg, TP53 , SLX4 , NF1 ) were observed in 47.4% of US and 18.2% of other subtypes. Potentially actionable variants ( KIT , PIK3CA ) were seen in 5.8%. Overall, RNA-NGS was clinically informative in 50%, refined diagnosis in 41.1%, and influenced treatment in 26.4% of patients. CONCLUSION: To our knowledge, this first-of-its-kind study highlights the clinical utility of integrating targeted RNA-based NGS into multidisciplinary sarcoma care, enabling diagnostic reclassification in 41.1% of cases most notably in round cell sarcomas with atypical morphology. Both canonical and rare fusions informed individualized therapy, reinforcing RNA-NGS as a pivotal tool for diagnostic refinement and precision oncology in sarcoma management.

18 August 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DSDr Nihanthy D S
Dr Nihanthy D S
SPSuresh Pandalanghat
Suresh Pandalanghat
AKAmul Kapoor
Amul Kapoor
RGRajath Govind
Rajath Govind
MKM. R. Kaushik
M. R. Kaushik
DMDeepak Mulajker
Deepak Mulajker
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as Palbociclib and Ribociclib, have significantly improved outcomes for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Although clinical trials have established the efficacy of these agents globally, real-world data from India is limited. This study compares the clinical effectiveness and safety profiles of Palbociclib and Ribociclib in a cohort of Indian patients. This prospective study included 60 patients with metastatic HR+/HER2- breast cancer treated at Army hospitals and research centers in India between 2020 and 2023. Progression-free survival (PFS), overall survival (OS), and safety profiles were analyzed to assess the real-world performance of Palbociclib and Ribociclib. Patients were treated with either Palbociclib or Ribociclib in combination with standard endocrine therapy. Among the 60 patients, the median PFS was 39.40 months for the Palbociclib group and 42.93 months for the Ribociclib group (p = 0.26), indicating no statistically significant difference. The median OS was 41.98 months in the Palbociclib group and 45.51 months in the Ribociclib group (p = 0.15), with Ribociclib showing a slight but non-significant survival advantage. The most common adverse event was neutropenia, which occurred in 26% of patients receiving Palbociclib and 23% of patients on Ribociclib. Deranged liver function tests (LFTs) and fatigue were also reported in both groups. Palbociclib and Ribociclib demonstrated comparable efficacy and safety profiles in this Indian cohort. While no statistically significant differences in PFS or OS were observed, the data suggest a marginal survival benefit with Ribociclib. These findings underscore the importance of individualized treatment plans in HR+/HER2- breast cancer, taking into consideration patient-specific factors. Larger studies with longer follow-up are needed to further clarify the nuances between these two agents.

18 January 2025 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DSDr Nihanthy D S
Dr Nihanthy D S
RGRajath Govind
Rajath Govind
NKNaveen Kumar Kushwaha
Naveen Kumar Kushwaha
LKLalit Kashyap
Lalit Kashyap

1 September 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
DKDr Naveen kumar Kushwaha
Dr Naveen kumar Kushwaha
DSDr Nihanthy D S
Dr Nihanthy D S

1 June 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
KSKaran Sood
Karan Sood
AAAmol Akhade
Amol Akhade
DSDr Nihanthy D S
Dr Nihanthy D S
SSSakshi Shimpi
Sakshi Shimpi
PURPOSE: In low- and middle-income countries (LMICs), access to traditional oncology education through conferences, journals, and in-person mentorship is often restricted. Social media has emerged as a potential tool to bridge this gap; however, its educational and clinical influence on oncology professionals remains underexplored. METHODS: We conducted a cross-sectional, anonymized, web-based survey of 202 oncology professionals from 13 countries. A 30-item questionnaire was used for the survey. Data were analyzed using descriptive statistics and chi-square tests. RESULTS: Among the respondents, 93% practiced in India, with 61% identifying Twitter (X) as their primary oncology information source. Daily engagement was reported by 53% of the respondents. The most valued benefits were early access to emerging research (30%) and trial updates (29%). Social media discussions atleast moderately influenced clinical decision making in 75% of respondents, with 29% reporting a substantial impact, which was a subjective assessment of the participants. Virtual tumor boards engaged 58% of the participants and prompted practice changes in 21%. Sixty-eight percent credited social media, with expanding their professional networks, and 25% initiated research collaborations through these platforms. Structured digital literacy training and tools, such as automated fact-checking and professional credential verification, were supported by over two thirds of the participants. CONCLUSION: Social media has become an essential educational and collaborative platform for oncology professionals, particularly in LMICs. By enabling timely access to research and supporting peer learning, it complements the traditional modes of oncology education. The formal integration of digital literacy training and content-verification mechanisms may enhance its safe and equitable use.

20 February 2025 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
DSDr Nihanthy D S
Dr Nihanthy D S
DKDr Naveen kumar Kushwaha
Dr Naveen kumar Kushwaha
KRKaushik M. R.
Kaushik M. R.
RGRajath Govind
Rajath Govind
Background In India, around 55,000 patients are on dialysis, with a 10–20% annual increase. With the growing dialysis population in India, cancer risk among end-stage renal disease (ESRD) patients is increasing. Managing chemotherapy in these patients is challenging due to limited data and guidelines, leading to treatment uncertainty. Objectives This study provides real-world data from India on the clinical management and outcomes of cancer patients with ESRD undergoing dialysis while receiving chemotherapy. Material and Methods This prospective study analyzed data from five cancer patients with end-stage renal disease (ESRD) on hemodialysis prior to diagnosis of cancer treated at a tertiary oncology center in India. We analyzed the demographic details, cancer staging, treatment regimens, and dosage adjustments. Treatment modifications due to renal dysfunction, toxicities, and patient outcomes were also reviewed over a 12-month follow-up. Results The cohort consisted of 80% (4/5 pts) females, with a median age of 57.8 years. Hypertensive and diabetic nephropathy were the leading causes of ESRD. Cancers included breast (3/5 pts), lung (1/5 pts), and ovarian (1/5 pts), with varying stages of diagnosis. 80% (4/5) of patients required tailored drug management. The Ovarian cancer patient experienced severe hypersensitivity to carboplatin, which was managed conservatively. No grade 3/4 immune-related adverse events occurred, and all patients were alive and disease-free at the one-year follow-up. Conclusion Carefully tailored treatment strategies and a coordinated multidisciplinary approach allowed positive outcomes for cancer patients on dialysis, emphasizing the need for personalized approaches. These findings highlight the importance of refining treatment protocols for this complex group.